ArticleCase reports in oncological medicine2020

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML.

Kousuke Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.